NCT07537257 2026-04-17
VEN+IDAC vs IDAC in AML
Guangdong Second Provincial General Hospital
Phase 2/3 Enrolling by invitation
Clinical Trials
11 trialsNCT06788756 2026-04-13
L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
Moleculin Biotech, Inc.
Phase 2/3 Recruiting
NCT04256317 2026-04-03
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Taiho Oncology, Inc.
Phase 2/3 Recruiting
NCT07255872 2026-03-05
A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2/3 Not yet recruiting
NCT07425808 2026-02-23
FIT-AML
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2/3 Not yet recruiting
NCT04708054 2026-02-19
Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
M.D. Anderson Cancer Center
Phase 2/3 Recruiting
NCT07366801 2026-01-26
Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 2/3 Recruiting
NCT03701308 2026-01-21
Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
National Cancer Institute (NCI)
Phase 2/3 Active not recruiting
NCT07264010 2025-12-04
Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study
Nanfang Hospital, Southern Medical University
Phase 2/3 Not yet recruiting
NCT07157514 2025-09-10
Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML
Actinium Pharmaceuticals
Phase 2/3 Not yet recruiting
NCT05356169 2025-05-30
Intensive Therapy Combined With Venetoclax for Adult Acute Myeloid Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Phase 2/3 Active not recruiting